MX2010009641A - Cristal de compuestos de bencimidazol. - Google Patents
Cristal de compuestos de bencimidazol.Info
- Publication number
- MX2010009641A MX2010009641A MX2010009641A MX2010009641A MX2010009641A MX 2010009641 A MX2010009641 A MX 2010009641A MX 2010009641 A MX2010009641 A MX 2010009641A MX 2010009641 A MX2010009641 A MX 2010009641A MX 2010009641 A MX2010009641 A MX 2010009641A
- Authority
- MX
- Mexico
- Prior art keywords
- crystal
- benzimidazole compound
- methyl
- benzimidazole
- trifluoroethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se provee un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)- 2-piridinil]metil]sulfinil]-1H-bencimidazol que muestra un patrón de análisis de difracción de rayos X de polvo con picos característicos en espacios interpianos (d) de 10.06±0.2, 8.70±0.2, 6.57±0.2, 5.59±0.2 y 4.00±0.2 Angstroms. La presente invención provee un fármaco anti-ulceroso estable superior en la capacidad de absorción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008059342 | 2008-03-10 | ||
| PCT/JP2009/054970 WO2009113696A1 (en) | 2008-03-10 | 2009-03-09 | Crystal of benzimidazole compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010009641A true MX2010009641A (es) | 2010-09-22 |
Family
ID=40577894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009641A MX2010009641A (es) | 2008-03-10 | 2009-03-09 | Cristal de compuestos de bencimidazol. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8222422B2 (es) |
| EP (1) | EP2262790B1 (es) |
| JP (3) | JP2011513202A (es) |
| KR (1) | KR20100123758A (es) |
| CN (1) | CN102026994B (es) |
| AR (1) | AR070972A1 (es) |
| AU (1) | AU2009224247B2 (es) |
| BR (1) | BRPI0909651A2 (es) |
| CA (1) | CA2671369C (es) |
| CL (1) | CL2009000547A1 (es) |
| CO (1) | CO6300956A2 (es) |
| CR (1) | CR11707A (es) |
| DO (1) | DOP2010000274A (es) |
| EA (1) | EA017064B1 (es) |
| EC (1) | ECSP10010531A (es) |
| ES (1) | ES2638463T3 (es) |
| GE (1) | GEP20125649B (es) |
| IL (1) | IL207867A0 (es) |
| LT (1) | LT2262790T (es) |
| MA (1) | MA32215B1 (es) |
| MX (1) | MX2010009641A (es) |
| MY (1) | MY150833A (es) |
| NZ (1) | NZ588379A (es) |
| PE (1) | PE20091680A1 (es) |
| PT (1) | PT2262790T (es) |
| TW (1) | TWI447110B (es) |
| UA (1) | UA103189C2 (es) |
| UY (1) | UY31695A (es) |
| WO (1) | WO2009113696A1 (es) |
| ZA (1) | ZA201006754B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011004387A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
| CN102108077B (zh) * | 2009-12-23 | 2013-09-25 | 江苏豪森医药集团有限公司 | 制备右兰索拉唑的方法 |
| WO2011092665A1 (en) * | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline forms of dexlansoprazole |
| CN104447695A (zh) * | 2013-11-22 | 2015-03-25 | 广东东阳光药业有限公司 | 一种苯并咪唑化合物的水合物 |
| PT3305291T (pt) | 2015-06-08 | 2021-07-05 | Hk Inno N Corp | Utilizações do derivado de benzimidazol para secreção ácida nocturna |
| IL266955B2 (en) * | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| CN106866631A (zh) * | 2017-04-06 | 2017-06-20 | 山东裕欣药业有限公司 | 一种右旋兰索拉唑晶型及制备方法 |
| BR112020003865A8 (pt) | 2017-09-01 | 2022-08-16 | Censa Pharmaceuticals Inc | Composições farmacêuticas compreendendo sepiapterina e seus usos |
| CN112469413B (zh) * | 2018-05-25 | 2024-01-12 | 伊马拉公司 | 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态 |
| EP3822249A4 (en) * | 2018-07-13 | 2022-04-13 | Kyowa Hakko Bio Co., Ltd. | CRYSTAL OF EUCOMIC ACID NONSOLVATE AND METHOD OF PREPARATION THEREOF |
| CN113376273B (zh) * | 2021-06-02 | 2023-03-17 | 国药集团精方（安徽）药业股份有限公司 | 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| DK171989B1 (da) | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
| DE4035455A1 (de) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
| SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| GB9423968D0 (en) | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
| HRP960232A2 (en) | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| HUP9904073A3 (en) | 1996-11-22 | 2000-04-28 | Procter & Gamble | Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| EP0903345B1 (de) * | 1997-08-08 | 2000-10-04 | Aventis Pharma Deutschland GmbH | Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid |
| WO1999038512A1 (en) | 1998-01-30 | 1999-08-05 | Sepracor Inc. | S-lansoprazole compositions and methods |
| JP2002501897A (ja) | 1998-01-30 | 2002-01-22 | セプラコール， インク． | Ｒ−ランソプラゾール組成物及び方法 |
| EP1075267A2 (en) | 1998-05-06 | 2001-02-14 | Kobenhavns Universitet | Treatment of celiac disease |
| JP3283252B2 (ja) * | 1999-06-17 | 2002-05-20 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
| TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| JP3374314B2 (ja) * | 2000-05-15 | 2003-02-04 | 武田薬品工業株式会社 | 結晶の製造法 |
| ES2511774T3 (es) * | 2000-05-15 | 2014-10-23 | Takeda Pharmaceutical Company Limited | Formas cristalinas de (R)-lansoprazol |
| JP4327424B2 (ja) * | 2000-05-15 | 2009-09-09 | 武田薬品工業株式会社 | 結晶の製造法 |
| HU229356B1 (en) * | 2000-12-01 | 2013-11-28 | Takeda Pharmaceutical | Process for the crystallization of (r)- or (s)-lansoprazole |
| JP4160293B2 (ja) * | 2000-12-01 | 2008-10-01 | 武田薬品工業株式会社 | 結晶の製造法 |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| ES2534713T3 (es) | 2002-10-16 | 2015-04-27 | Takeda Pharmaceutical Company Limited | Preparaciones sólidas estables |
| WO2009088857A1 (en) | 2007-12-31 | 2009-07-16 | Takeda Pharmaceutical Company Limited | Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole |
-
2009
- 2009-03-09 UA UAA201011966A patent/UA103189C2/ru unknown
- 2009-03-09 CA CA2671369A patent/CA2671369C/en active Active
- 2009-03-09 KR KR1020107022471A patent/KR20100123758A/ko not_active Application Discontinuation
- 2009-03-09 MY MYPI20104206 patent/MY150833A/en unknown
- 2009-03-09 LT LTEP09719483.1T patent/LT2262790T/lt unknown
- 2009-03-09 JP JP2010535143A patent/JP2011513202A/ja active Pending
- 2009-03-09 MX MX2010009641A patent/MX2010009641A/es active IP Right Grant
- 2009-03-09 WO PCT/JP2009/054970 patent/WO2009113696A1/en active Application Filing
- 2009-03-09 EA EA201071053A patent/EA017064B1/ru not_active IP Right Cessation
- 2009-03-09 PT PT97194831T patent/PT2262790T/pt unknown
- 2009-03-09 NZ NZ588379A patent/NZ588379A/en not_active IP Right Cessation
- 2009-03-09 GE GEAP200911968A patent/GEP20125649B/en unknown
- 2009-03-09 CL CL2009000547A patent/CL2009000547A1/es unknown
- 2009-03-09 AU AU2009224247A patent/AU2009224247B2/en not_active Ceased
- 2009-03-09 TW TW098107510A patent/TWI447110B/zh active
- 2009-03-09 ES ES09719483.1T patent/ES2638463T3/es active Active
- 2009-03-09 UY UY0001031695A patent/UY31695A/es not_active Application Discontinuation
- 2009-03-09 EP EP09719483.1A patent/EP2262790B1/en active Active
- 2009-03-09 US US12/921,682 patent/US8222422B2/en active Active
- 2009-03-09 AR ARP090100831A patent/AR070972A1/es not_active Application Discontinuation
- 2009-03-09 CN CN200980116767.8A patent/CN102026994B/zh active Active
- 2009-03-09 BR BRPI0909651A patent/BRPI0909651A2/pt not_active IP Right Cessation
- 2009-03-09 PE PE2009000341A patent/PE20091680A1/es not_active Application Discontinuation
-
2010
- 2010-08-30 IL IL207867A patent/IL207867A0/en unknown
- 2010-09-10 DO DO2010000274A patent/DOP2010000274A/es unknown
- 2010-09-21 ZA ZA2010/06754A patent/ZA201006754B/en unknown
- 2010-09-30 CR CR11707A patent/CR11707A/es not_active Application Discontinuation
- 2010-10-07 CO CO10124417A patent/CO6300956A2/es not_active Application Discontinuation
- 2010-10-07 MA MA33231A patent/MA32215B1/fr unknown
- 2010-10-08 EC EC2010010531A patent/ECSP10010531A/es unknown
-
2013
- 2013-09-27 JP JP2013202604A patent/JP2014015477A/ja active Pending
-
2015
- 2015-04-27 JP JP2015090379A patent/JP2015163623A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY150833A (en) | Crystal of benzimidazole compound | |
| AR103295A2 (es) | Compuesto cristalino de benzimidazol, composición farmacéutica que lo comprende y método para la manufactura de dicha composición | |
| JP2011507977A5 (es) | ||
| TNSN08089A1 (en) | Substituted benzimidazoles and methods of preparation | |
| CA2701704A1 (en) | Process for producing crystal | |
| ZA200900505B (en) | N-(Aminoheteroaryl)-1 H-Indole-2-Carboxamide derivatives, and preparation and thepateutic application thereof | |
| GEP20084341B (en) | Aminoheteroaryl compounds as protein kinase inhibitors | |
| IL190437A (en) | Use of 3– (4 – amino – 1 – oxo – 3,1 – dihydro-isoindole – 2 – ile) –pipridine – 6,2 – discussion for the preparation of a drug for the treatment of certain leukemias | |
| WO2012001156A3 (en) | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts | |
| EP2280955B8 (en) | Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | |
| IL172266A0 (en) | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | |
| MX2009006529A (es) | Formas cristalinas de ilaprazol solvatado. | |
| WO2008045777A3 (en) | A process for the preparation of benzimidazole derivatives and their salts | |
| WO2008027523A3 (en) | Salts of benzimidazolyl pyridyl ethers and formulations thereof | |
| ZA989999B (en) | New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole | |
| IL206657A (en) | Transformed oxindole derivatives, the pharmaceutical compositions containing them and their use in the preparation of drugs for the treatment of vasopressin-dependent diseases | |
| WO2011042910A3 (en) | Optical resolution of substituted 2-(2- pyridinylmethylsulphinyl)-1h-benzimidazoles | |
| TN2010000400A1 (en) | Crystal of benzimidazole compound | |
| AU2000258410A1 (en) | New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole | |
| IL185370A0 (en) | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | |
| WO2009066309A3 (en) | Process for preparation of omeprazole | |
| BRPI0515484A (pt) | derivados piridìnicos de indolin-2-ona, o respectivo preparo e a respectiva aplicação em terapêutica | |
| HUP0600347A3 (en) | Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon) and the intermediate | |
| WO2007126826A3 (en) | Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives | |
| ECSP003736A (es) | Procedimiento mejorado para la preparacion de derivados de bencimidazol adecuados como farmacos antiulcerosos, particularmente omeprazol o pantoprazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |